LucentAD® Complete
Assessment of Alzheimer's Disease Pathology
Key Facts
About Lucent Diagnostics
Lucent Diagnostics is dedicated to transforming Alzheimer's detection and diagnosis by making highly-sensitive, accessible blood tests the new standard of care. Its core offerings are the LucentAD® Complete and LucentAD® p-Tau217 tests, which utilize the ultrasensitive Simoa® platform to identify Alzheimer's-related biomarkers. As a commercial-stage diagnostics brand under the publicly-traded Quanterix Corporation, it aims to empower healthcare providers with tools for earlier intervention and improved patient outcomes in the rapidly evolving Alzheimer's therapeutic landscape.
View full company profileAbout Quanterix
Quanterix's mission is to accelerate the understanding of biology and the detection of disease through ultra-sensitive biomarker measurement. Its core achievement is the development and global commercialization of the Simoa platform, which is the gold standard for digital immunoassays, supported by over 5,000 peer-reviewed publications and partnerships with top pharmaceutical companies. The company's strategy is a 'full-spectrum' approach, combining its leading liquid biopsy capabilities with spatial proteomics from Akoya to provide integrated insights from blood to tissue. This positions Quanterix to capture value across the entire biomarker continuum, from research and drug development to clinical diagnostics.
View full company profile